论文部分内容阅读
急性淋巴细胞白血病(ALL)微量残留病变(MRD)的检测可以确定亚临床水平的疾患。以IgH基因第三互补决定区(CDR-Ⅲ)重排作为克隆特异的基因标记,应用聚合酶链反应(PCR)技术研究MRD,检测水平达到10~4～10~5正常骨髓细胞中1个白血病细胞,超过光学显微镜形态学观察量值的2～3倍。作者对14例复发与缓解的ALL患儿MRD作回顾性比较研究。14例ALL受试患者诊断时年龄1.0～20岁
Detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) can determine subclinical disorders. The rearrangement of the third complementarity-determining region (CDR-III) of the IgH gene was used as a clone-specific gene marker. Polymerase chain reaction (PCR) was used to study MRD, and one of the normal bone marrow cells was detected at a level of 10~4~10~5. Leukemia cells exceed 2 to 3 times the morphological observation value of the light microscope. The authors retrospectively compared MRD findings in 14 children with ALL who had relapsed or remitted ALL. 14 cases of ALL patients diagnosed at the age of 1.0 to 20 years old